Barriers to Progress: Why Personalized Medicine Hasn't Developed for Chronic Conditions
Chronic conditions—asthma, hypertension, diabetes, depression, and others—are widely prevalent and have a significant impact on long-term healthcare costs. Diagnostic targeting of drug therapies in treatment may improve response rates and adherence, producing both clinical and economic benefits. But first, some current care delivery and infrastructure paradigms have to change.
Key aspects of the community care delivery model, including test reporting and clinical practice management, tend to act as barriers to targeting chronic disease therapy. For diagnostic drug targeting to gain acceptance in the treatment of chronic diseases, manufactures will need to address these issues—ensuring short-term economic and practice incentives align with long-term clinical benefits